Abstracts Archive - Page 246 of 1683 - ATC Abstracts

2021 American Transplant Congress
The Clinical Significance of Preformed Anti-HLA-DQ Donor-specific Antibodies on Allograft Outcomes in Kidney Transplantation
S. Lee¹, C. Yang², B. Chung²
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: De-novo anti-HLA-DQ donor-specific antibody (DSA) has been identified as a risk factor for late graft dysfunction and graft loss in kidney transplantation (KT). The…
2021 American Transplant Congress
De Novo Membranous Nephropathy Associated with Antibody-mediated Rejection in Renal Transplant Recipients
M. V. Sousa¹, L. G. Fernandes², L. L. de Freitas³, R. L. Zollner², M. Mazzali¹
¹Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, ²Internal Medicine, University of Campinas, Campinas, Brazil, ³Pathology, University of Campinas, Campinas, Brazil
*Purpose: Membranous nephropathy (MN) is a rare autoimmune disease, with the potential to develop a persistent nephrotic syndrome and end-stage chronic renal disease in some…
2021 American Transplant Congress
Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
B. Shin, S. Ge, A. Jimenez, N. Ammerman, A. Vo, R. Zhang, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Cerritos, CA
*Purpose: IL-6 is a pro-inflammatory cytokine responsible for chronic vascular inflammation and a promising target for cABMR modulation. IL-6/sIL-6R complex initiates more pathogenic trans-signaling pathways…
2021 American Transplant Congress
Treatment and Outcomes of Kidney Transplant Recipients with C4d Negative Antibody Mediated Rejection
M. Walsh, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study is to describe and evaluate treatment practices and patient outcomes for kidney transplant recipients with presence of C4d negative…
2021 American Transplant Congress
Risk Factors and Outcome of Transplant Renal Artery Stenosis in Kidney Transplant Recipients – A Nested Case-control Study
D. Choudhary¹, A. Sharma¹, R. Vijayvergiya², G. Kasinadhuni², D. Kenwar¹, S. Singh¹
¹Renal & Pancreas Transplant Surgery, Pgimer Chandigarh, Chandigarh, India, ²Cardiology, Pgimer Chandigarh, Chandigarh, India
*Purpose: Transplant renal artery stenosis (TRAS) is a treatable cause of renal allograft dysfunction. It presents commonly in the early post-transplant period with variable clinical…
2021 American Transplant Congress
Hypercholesterolemia and Donor Age Impaired Capillary Vegf and Nitric Oxide (no) Expression and in Turn Decrease Both Microvascular Density and Tubule Villin Expression in Renal Allografts, Resulting in Poor Graft Survival
B. Ozdemir¹, E. Akcay¹, A. Ok Atilgan¹, M. Haberal²
¹Department of Pathology, Baskent University, Ankara, Turkey, ²Division of Transplantation, Department of General Surgery, Baskent University, Ankara, Turkey
*Purpose: The role of aging and hypercholesterolemia (HC) on endothelial cells (ECs) are not well defined. Aged ECs might produce less NO and VEGF, resulting…
2021 American Transplant Congress
Psmp is Discriminative for Chronic Active Antibody-Mediated Rejection and Predicts Graft Risk After Kidney Transplantation
Y. Fu, P. Zhan
Tianjin First Central Hospital, Tianjin, China
*Purpose: Chronic active antibody-mediated rejection (c-aABMR) is an intermediate process in the development of chronic antibody-mediated rejection (c-ABMR), a key problem in the long-term failure…
2021 American Transplant Congress
Impact of Donated Kidney Volume and Recipient Body Surface Area Incompatibility on the Allograft Outcomes with Pre-transplant Diabetes Mellitus
Y. Park¹, H. Lee², E. Ko², C. Yang², B. Chung²
¹Internal Medicine, Konyang University Hospital, Daejeon, Korea, Republic of, ²Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
*Purpose: The aim of this study was to analyze the impact on the adverse allograft outcome of transplanting relative small kidneys in patients with pre-transplant…
2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸
¹University of Manitoba, Winnipeg, MB, Canada, ²Medical University of Vienna, Vienna, Austria, ³University of Sydney, Sydney, Australia, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷CSL Behring, King of Prussia, PA, ⁸University of Wisconsin, Madison, WI
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…
2021 American Transplant Congress
Utility of Donor-Derived Cell Free DNA for Detecting ABMR in Patients With AT1R Antibodies
S. Kant¹, D. Kumar², I. Moinuddin², T. Alhamad³, M. Haris³, J. Gray⁴, B. Dale⁴, M. Bettinotti¹, D. C. Brennan¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²VCU, Richmond, VA, ³Wash Univ, St. Louis, MO, ⁴CareDx, Brisbane, CA
*Purpose: The presence of angiotensin II type 1 receptor (AT1R) antibodies is associated with non-HLA active antibody mediated rejection (ABMR). The frequent co-existence of negative…